<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01567956</url>
  </required_header>
  <id_info>
    <org_study_id>ST261DM11006</org_study_id>
    <secondary_id>2011-004770-28</secondary_id>
    <nct_id>NCT01567956</nct_id>
  </id_info>
  <brief_title>Propionyl-L-Carnitine Hydrochloride in Patients With Mild Ulcerative Colitis; Efficacy, Safety and Tolerability Study</brief_title>
  <official_title>Phase III Randomized Multicenter International Study to Investigate the Safety and Efficacy of Propionyl-L-Carnitine Hydrochloride Modified Release Tablets in Patients Affected by Mild Ulcerative Colitis Under Oral Stable Treatment</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>sigma-tau i.f.r. S.p.A.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>PRA Health Sciences</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>sigma-tau i.f.r. S.p.A.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of the trial is to test safety, tolerability and efficacy of Propionyl-L-carnitine
      modified release tablets 1g/die in reducing the symptoms of the disease with respect to the
      proportion of patients with disease remission at the end of the 8 weeks of treatment. It will
      also aim to investigate capability of the treatment in the maintenance of remission after
      four weeks of treatment interruption; histological changes will be also evaluated and
      finally, improvement in the overall quality of life as measured by the Short Inflammatory
      Bowel Disease Questionnaire (SIBDQ) will be investigated.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Although it seems clear that an abnormal function of the colonic epithelium is the central
      problem causing inflammation and the unusual immunological response to the normal gut flora
      in inflammatory bowel disease (IBD), the actual causes of these dysfunctions are still
      unknown. Short Chain Fatty Acids (SCFA) are the main fuel of the colonic epithelium, and are
      normally produced by the bacterial flora by fermentation of the complex carbohydrates forming
      non soluble fibers usually introduced with everyday diet. Butyrate alone contributes 70% of
      the normal colonocyte energy. Studies done using animal models and colonic mucosa biopsies
      from patients suffering form ulcerative colitis (UC) have consistently shown that a metabolic
      change occurs in diseased colonic mucosa, with an impairment of butyrate oxidation (and of
      beta-oxidation) and an energy shortage that is only incompletely compensated by oxidation of
      glucose and other substrates such as glutamine. It is also well known that matrix
      metalloproteases production is highly increased in IBD and that serum transglutaminase
      activity is significantly reduced in patients with IBD. Transglutaminases are enzymes
      contributing to the crosslinking of matrix proteins and the reduction seen in patients
      affected by IBD correlates well with the endoscopic and histopathologic grading in UC,
      meaning that part of the circulating enzyme is sequestered in the injured colonic tissue in
      the effort to re-build the extracellular matrix during the healing process.
      Propionyl-L-carnitine Hydrochloride (PLC) is a molecule that has already been shown to reduce
      membrane lipid peroxidation in endothelial cells from bovine aorta and coronary vessels, to
      reduce the effects of hypoxia in coronary endothelial cells, and to play a role in the
      cardiac metabolic abnormalities that contribute to the mechanical dysfunctions leading to
      heart failure. Given these properties of Propionyl-L-carnitine Hydrochloride (ST 261) and
      given the peroxidative damage suffered by colonocytes in UC together with their metabolic
      impairment, the use of this molecule for the treatment of UC seemed to be appropriate and
      sound, in particular as a carrier of a propionate moiety that, once transformed into
      succinate, enters the Kreb cycle, acting as an extra burst fuel improving the balance of
      energy production inside tissues. Previous clinical experience has shown that PLC promoted
      complete or nearly complete regression of cutaneous trophic ulcers in a large number of
      vasculopathic patients refractory to all other therapies. As far as the UC pathology is
      concerned, the effects of ST 261, given orally or intrarectally, were investigated at
      different dosages, in preclinical experimentation, either after a single trinitrobenzene
      sulphonic acid (TNBS) administration (acute colitis) or after repeated TNBS administrations
      (reactivated colitis). The results showed a reduction in the damaged colon area both in acute
      model and reactivated colitis, even if the beneficial effect of restoration of TNBS-induced
      alterations of tissue morphology is more evident in the reactivated colitis model,
      particularly after oral administration. Based on the above-described results a development
      plan in humans started to investigate the activity of PLC in the treatment of ulcerative
      colitis.
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Evidence of very low probability to success. No safety issues
  </why_stopped>
  <start_date>April 2012</start_date>
  <completion_date type="Actual">January 2014</completion_date>
  <primary_completion_date type="Actual">October 2013</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Proportion of clinical/endoscopic remissions</measure>
    <time_frame>End of treatment (week 8)</time_frame>
    <description>Remission will be defined according with the overall modified Mayo score (Disease Activity Index). A score â‰¤ 2 with rectal bleeding sub-score = 0 and no other individual sub-score &gt;1 will be considered necessary to classify the patient in remission state.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in Rectal bleeding evaluation</measure>
    <time_frame>At week 2, 6 and 8 of treatment and after 4 week follow-up</time_frame>
    <description>Evaluation will be performed by means of Disease Activity Index (DAI) sub-score (from 0 to 3).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in stool frequency evaluation</measure>
    <time_frame>At week 2, 6 and 8 of treatment and after 4 week follow-up</time_frame>
    <description>Evaluations will be performed by means of Disease Activity Index (DAI) sub-score (from 0 to 3).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Histological response to the treatment</measure>
    <time_frame>End of treatment (week 8)</time_frame>
    <description>Evaluated as an improvement of the histological index of at least 1 point</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in C-reactive protein (CRP) and Fibrinogen</measure>
    <time_frame>End of the treatment (week 8) and after 4 week follow-up</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Improvement of patients quality of life</measure>
    <time_frame>End of treatment period (week8) and after 4 week follow-up</time_frame>
    <description>A validated specific questionnaire, the SIBDQ by McMaster university will be administered to evaluate changes in patients' quality of life</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Haematology</measure>
    <time_frame>Baseline and end of treatment (week8)</time_frame>
    <description>Haemoglobin, Haematocrit, RBC, WBC and differential count.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Electrocardiogram</measure>
    <time_frame>At baseline and at the end of treatment period (week8)</time_frame>
    <description>Standard intervals (PR, RR, QRS, QT) will be collected plus all rhythm abnormalities</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse Events collection</measure>
    <time_frame>12 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum Chemistry</measure>
    <time_frame>At baseline and at the end of treatment period (week8)</time_frame>
    <description>Standard evaluation including renal and liver function, electrolytes and blood glucose</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">150</enrollment>
  <condition>Ulcerative Colitis</condition>
  <arm_group>
    <arm_group_label>Propionyl-L-Carnitine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Modified release tablets containing 500 mg of propionyl-L-carnitine</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Modified release tablets containing inert substances</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Propionyl-L-Carnitine</intervention_name>
    <description>500 mg modified release tablets, 500 mg bid; treatment duration 8 weeks</description>
    <arm_group_label>Propionyl-L-Carnitine</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>500 mg inert substances modified release tablets, 500 mg bid; treatment duration 8 weeks</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Have read the Information for the Patient and signed the Informed Consent Form.

          -  Diagnosis of active ulcerative colitis since at least 4 weeks as confirmed
             endoscopically and histologically.

          -  Disease Activity Index comprised between 3 and 6, inclusive (mild ulcerative colitis),
             with rectal bleeding sub-score of at least 1.

          -  Stable background oral aminosalicylates (mesalazine, balsalazide, olsalazine) or
             sulfasalazine standard therapy for greater than or equal to 4 weeks prior to screening
             assessments.

          -  If female, not pregnant or nursing. For women of childbearing potential, willingness
             to avoid a pregnancy during the treatment period and for at least 4 weeks from the
             last dose of drug and utilization of an efficient method of birth control for the
             entire duration of the trial and until the first menses after a 30-day period after
             the last dose of trial medication.

        Exclusion Criteria:

          -  Crohn's disease and indeterminate colitis.

          -  Current or previous (in the last 10 days preceding the screening) use of systemic
             corticosteroids.

          -  Use of systemic antibiotics in the last 10 days preceding the screening.

          -  Use of systemic Nonsteroidal anti-inflammatory drugs on a repeat basis in the last 10
             days preceding the screening.

          -  Use of probiotics started within 10 days preceding the screening. A stable regimen
             from at least 10 days prior to screening is allowed but the patient must be willing to
             continue up to the end of the study.

          -  Use of immunosuppressants or biological agents within the last 6 weeks preceding the
             screening.

          -  Treatment with L-carnitine or its esters derivatives within the last 3 months.

          -  Stool culture positive for enteric pathogens (eg, Shigella, Salmonella, Yersinia,
             Campylobacter) or toxins (C.difficile).

          -  Significantly impaired liver, renal, pulmonary or cardiovascular function as assessed
             by the investigator.

          -  History of colon resection.

          -  Diverticulitis, symptomatic diverticulosis.

          -  Active peptic ulcer disease.

          -  Proctitis (extent of inflammation &lt; 15 cm from the anus).

          -  Bleeding disorders

          -  Rectal therapy with any therapeutic enemas or suppositories with the exception of
             those required for endoscopy during the 10 days preceding the screening.

          -  Active or chronic infection(s) or malignancies.

          -  Known hypersensitivity to the active ingredient and excipients of the study drug

          -  Patients treated with L-Carnitine or its esters derivatives during the 3 months
             preceding the screening phase.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Sandro Ardizzone, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Head of Inflammatory Bowel Diseases Unit Hospital &quot;Luigi Sacco&quot; Milan - ITALY</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Landeskrankenhaus-UniversitÃ¤tskliniken Innsbruck - Klinische Abteilung fÃ¼r Gastroenterologie und Hepatologie</name>
      <address>
        <city>Innsbruck</city>
        <zip>6020</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Krankenhaus der Barmherzigen BrÃ¼der - Abteilung fÃ¼r Innere Medizin</name>
      <address>
        <city>Salzburg</city>
        <zip>5010</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ordinationszentrum DÃ¶bling</name>
      <address>
        <city>Vienna</city>
        <zip>1190</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Allgemeines Krankenhaus Wien - UniversitÃ¤tsklinik Klinik fÃ¼r Innere Medizin III</name>
      <address>
        <city>Wien</city>
        <zip>1090</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier Intercommunal CrÃ©teil 40 avenue de Verdun</name>
      <address>
        <city>Creteil</city>
        <zip>94010</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier Universitaire HÃ´pital Nord - Service D'HÃ©pato-Gastro-EntÃ©rologie</name>
      <address>
        <city>Marseille</city>
        <zip>13015</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier Universitaire Hotel Dieu Service d'hÃ©pato-gastroentÃ©rologie</name>
      <address>
        <city>Nantes</city>
        <zip>44000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>HÃ´pital de IÂ´Archet 2 Service d'HÃ©pato-GastroentÃ©rologie et de Nutrition Clinicque, PÃ´le Digestif</name>
      <address>
        <city>Nice cedex 3</city>
        <zip>06202</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>HÃ´pital Nord - Dept. of Gastroenterology</name>
      <address>
        <city>Picardie</city>
        <zip>80 054</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>HÃ´pital Robert DebrÃ© Service et Consultation d'HÃ©pato-Gastro-EntÃ©rologie</name>
      <address>
        <city>Reims cedex</city>
        <zip>51092</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hopital Nord - CHU de Saint-Etienne Service de Gastro-EntÃ©rologie</name>
      <address>
        <city>Saint-Etienne</city>
        <zip>42270</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>HÃ´pital Rangueil Service de gastro-enterologie</name>
      <address>
        <city>Toulouse Cedex 4</city>
        <zip>31079</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>HÃ´pital Brabois Service de gastro-enterologie</name>
      <address>
        <city>Vandoeuvre Les Nancy Cedex</city>
        <zip>54511</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CharitÃ© UniversitÃ¤tsmedizin Berlin UniversitÃ¤tsklinik CharitÃ©, Campus Mitte Medizinische Poliklinik</name>
      <address>
        <city>Berlin</city>
        <zip>10117</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Saint Josef Hospital Ruhr Universitaet Bochum GudrunstraÃŸe 56</name>
      <address>
        <city>Bochum</city>
        <zip>44791</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinikum Braunschweig</name>
      <address>
        <city>Braunschweig</city>
        <zip>38126</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UniversitÃ¤tsklinikum Dresden Medizinische Klinik und Poliklinik I</name>
      <address>
        <city>Dresden</city>
        <zip>01307</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UniverstÃ¤tsklinikum Schleswig-Holstein Gastroenterologie</name>
      <address>
        <city>LÃ¼beck</city>
        <zip>23538</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UniversitÃ¤tsklinikum Magdeburg A.Ã¶.R. Klinik fÃ¼r Gastroenterologie, Hepatologie und Infektiologie</name>
      <address>
        <city>Magdeburg</city>
        <zip>39120</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UniversitÃ¤tsmedizin Mannheim II. Medizinische Klinik</name>
      <address>
        <city>Mannheim</city>
        <zip>68167</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Praxis Prof. Dr. med. Herbert Kellner</name>
      <address>
        <city>MÃ¼nchen</city>
        <zip>80639</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UniversitÃ¤tklinikum MÃ¼nster Medizinische Klinik und Poliklinik fÃ¼r Innere Medizin</name>
      <address>
        <city>MÃ¼nster</city>
        <zip>48149</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Gastroenterologische Fachpraxis am Germania Campus</name>
      <address>
        <city>MÃ¼nster</city>
        <zip>48159</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Elbe Klinikum Stade Innere Medizin, Abteilung Gastroenterology</name>
      <address>
        <city>Stade</city>
        <zip>21682</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>FovÃ¡rosi Ã–nkormÃ¡nyzat PÃ©terfy SÃ¡ndor Utcai KÃ³rhÃ¡z</name>
      <address>
        <city>Budapest</city>
        <zip>1076</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Semmelweis Egyetem 1st Internal Dept.</name>
      <address>
        <city>Budapest</city>
        <zip>1083</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>PannÃ³nia MagÃ¡norvosi Centrum Kft.</name>
      <address>
        <city>Budapest</city>
        <zip>1136</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Semmelweis Egyetem II. sz. BelgyÃ³gyÃ¡szati Klinika</name>
      <address>
        <city>Budapest</city>
        <zip>H-1088</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>BÃ©kÃ©s Megyei KÃ©pviselotestÃ¼let PÃ¡ndy KÃ¡lmÃ¡n KÃ³rhÃ¡za Semmelweis ulica 1</name>
      <address>
        <city>Gyula</city>
        <zip>5700</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kaposi MÃ³r Megyei OktatÃ³ KÃ³rhaz BelgyÃ³gyÃ¡szati OsztÃ¡ly</name>
      <address>
        <city>KaposvÃ¡r</city>
        <zip>H-7400</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Borsod AbaÃºj ZemplÃ©n Megyei KÃ³rhÃ¡z Ã©s Egyetemi OktatÃ³ KÃ³rhÃ¡z II. sz. BelgyÃ³gyÃ¡szati OsztÃ¡ly</name>
      <address>
        <city>Miskolc</city>
        <zip>3526</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Karolina KÃ³rhÃ¡z RendelointÃ©zet BelgyÃ³gyÃ¡szat- GasztroenterolÃ³giai OsztÃ¡ly</name>
      <address>
        <city>MosonmagyarÃ³var</city>
        <zip>9200</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinfan Kft. SMO</name>
      <address>
        <city>SzekszÃ¡rd</city>
        <zip>7100</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CRU Hungary Kft.</name>
      <address>
        <city>SzikszÃ³</city>
        <zip>3800</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Daugavpils Central Regional Hospital</name>
      <address>
        <city>Daugavpils</city>
        <zip>LV-5400</zip>
        <country>Latvia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Paula Stradina Clinical University Hospital Gastroenterology Centre</name>
      <address>
        <city>Riga</city>
        <zip>LV-1002</zip>
        <country>Latvia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Latvian Maritime Medicine Centre</name>
      <address>
        <city>Riga</city>
        <zip>LV-1005</zip>
        <country>Latvia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Digestive Disease Center GASTRO</name>
      <address>
        <city>Riga</city>
        <zip>LV-1006</zip>
        <country>Latvia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Lietuvos sveikatos mokslu universiteto ligonine VÅ¡I Kauno klinikos Gastroenterologijos skyrius</name>
      <address>
        <city>Kaunas</city>
        <zip>LT-50009</zip>
        <country>Lithuania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klaipedos jurininku ligonine Diagnostikos skyrius</name>
      <address>
        <city>Klaipeda</city>
        <zip>LT-92288</zip>
        <country>Lithuania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>VÅ¡I Mykolo Marcinkeviciaus ligonines</name>
      <address>
        <city>Vilnius</city>
        <zip>LT-03215</zip>
        <country>Lithuania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Vilniaus universiteto ligonine SantariÅ¡kiu klinikos Hepatologijos, gastroenterologijos ir dietologijos centras</name>
      <address>
        <city>Vilnius</city>
        <zip>LT-08661</zip>
        <country>Lithuania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centrum Opieki Zdrowotnej Orkan-Med Stec-Michalska Sp.J</name>
      <address>
        <city>KsawerÃ³w</city>
        <zip>95-054</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>SPZOZ Uniwersytecki Szpital Kliniczny Nr 1 im. Norberta Barlickiego Oddzial Gastroenterologii OgÃ³lnej i Onkologicznej</name>
      <address>
        <city>LÃ³dz</city>
        <zip>90-153</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>WojewÃ³dzki Szpital Specjalistyczny w Olsztynie Oddzial Gastroenterologii</name>
      <address>
        <city>Olsztyn</city>
        <zip>10-561</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Endoskopia Sp. z o.o.</name>
      <address>
        <city>Sopot</city>
        <zip>81-756</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Nzoz Vivamed</name>
      <address>
        <city>Warszawa</city>
        <zip>03-580</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Akademicki Szpital Kliniczny im. Jana Mikulicza-Radeckiego we Wroclawiu Klinika Gastroenterologii i Hepatologii</name>
      <address>
        <city>Wroclaw</city>
        <zip>50-556</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Wojewodzki Szpital Specjalistyczny im. J. Gromkowskiego we Wroclawiu Oddzial Gastroenterologii</name>
      <address>
        <city>Wroclaw</city>
        <zip>51-149</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>LexMedica</name>
      <address>
        <city>Wroclaw</city>
        <zip>53-025</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>ARS MEDICA s.c., Rybak Maria, Rybak Zbigniew</name>
      <address>
        <city>Wroclaw</city>
        <zip>53-333</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>FundaciÃ³n Hospital de AlcorcÃ³n Servicio de GastroenterologÃ­a</name>
      <address>
        <city>AlcorcÃ³n</city>
        <zip>28922</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centro Medico Teknon Servicio de Aparato Disgestivo</name>
      <address>
        <city>Barcelona</city>
        <zip>08022</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Virgen de la Arrixaca Servicio de Digestivo</name>
      <address>
        <city>El Palmar</city>
        <zip>30120</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario La Princesa Unidad de HepatologÃ­a, Servicio de Gastroenterologia</name>
      <address>
        <city>Madrid</city>
        <zip>28006</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario La Paz Servico de Gastroenterologia</name>
      <address>
        <city>Madrid</city>
        <zip>28046</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CorporaciÃ³ Sanitaria Parc TaulÃ­ Servicio de Digestivo</name>
      <address>
        <city>Sabadell</city>
        <zip>08028</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Marques de Valdecilla Servicio de Digestivo</name>
      <address>
        <city>Santander</city>
        <zip>39008</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Austria</country>
    <country>France</country>
    <country>Germany</country>
    <country>Hungary</country>
    <country>Latvia</country>
    <country>Lithuania</country>
    <country>Poland</country>
    <country>Spain</country>
  </location_countries>
  <verification_date>April 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 28, 2012</study_first_submitted>
  <study_first_submitted_qc>March 29, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 30, 2012</study_first_posted>
  <last_update_submitted>November 4, 2016</last_update_submitted>
  <last_update_submitted_qc>November 4, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 7, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Ulcerative colitis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Colitis</mesh_term>
    <mesh_term>Ulcer</mesh_term>
    <mesh_term>Colitis, Ulcerative</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

